Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesionH I Scher, A Yagoda, H W Herr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-upP K Schultz, H W Herr, Z F Zhang, et al.
The Journal of Urology|March 1, 1985
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
Cancer|December 15, 1989
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapseC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1992
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancerD L Lamm, P M van der Meijden, A Morales, et al.
Critical Reviews in Oncology/Hematology|February 1, 1994
Bladder cancer: advances in biology and treatmentG J Bosl, W R Fair, H W Herr, et al.
The Journal of Urology|March 1, 1988
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urotheliumC N Sternberg, A Yagoda, H I Scher, et al.
The Journal of Urology|March 1, 1988
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumorsH I Scher, A Yagoda, H W Herr, et al.
Journal of the American College of Surgeons|May 1, 1995
Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990G W Jones, C Mettlin, G P Murphy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selectionG C Toner, D M Panicek, R T Heelan, et al.
Pageof 25